On this basis, it is possible or even likely that NLRC4 inflammasome activity, particularly when augmented by the presence of a particular genetic and/or environmental factor, can make an important contribution to CD-associated inflammation and its inhibition by LRRK2-kinase inhibition plays an important role in its overall ability to treat Crohn’s disease. This evidence concerns the gene LRRK2 and Crohn disease.